UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Clinical cancer research, 2019-05, Vol.25 (10), p.2975-2987

2019

Volltextzugriff (PDF)

Paclitaxel alters melanogenesis and causes pigmentation in the skin of gynecological cancer patients

Fundamental & clinical pharmacology, 2024-02, Vol.38 (1), p.183-191

2024

Volltextzugriff (PDF)

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-09, Vol.18 (17), p.4764-4774

2012

Volltextzugriff (PDF)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Breast cancer research : BCR, 2021-02, Vol.23 (1), p.26-18, Article 26

2021

Volltextzugriff (PDF)

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Breast cancer research : BCR, 2021-01, Vol.23 (1), p.8-8, Article 8

2021

Volltextzugriff (PDF)

Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model

International journal of molecular sciences, 2022-01, Vol.23 (3), p.1142

2022

Volltextzugriff (PDF)

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

Breast cancer research and treatment, 2009-04, Vol.114 (3), p.479-484

2009

Volltextzugriff (PDF)

Timing of Meals and Sleep in the Mediterranean Population: The Effect of Taste, Genetics, Environmental Determinants, and Interactions on Obesity Phenotypes

Nutrients, 2023-01, Vol.15 (3), p.708

2023

Volltextzugriff (PDF)

Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus

Journal of Gynecologic Oncology, 2023, 34(5), , pp.1-21

2023

Volltextzugriff (PDF)

Aurora kinases in ovarian cancer

ESMO open, 2020-10, Vol.5 (5), p.e000718-e000718, Article e000718

2020

Volltextzugriff (PDF)

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

Breast cancer research and treatment, 2014-02, Vol.143 (3), p.507-515

2014

Volltextzugriff (PDF)

Chronological Age Interacts with the Circadian Melatonin Receptor 1B Gene Variation, Determining Fasting Glucose Concentrations in Mediterranean Populations. Additional Analyses on Type-2 Diabetes Risk

Nutrients, 2020-10, Vol.12 (11), p.3323

2020

Volltextzugriff (PDF)

Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways

Cancer treatment reviews, 2012-10, Vol.38 (6), p.698-707

2012

Volltextzugriff (PDF)

Associations between the New DNA-Methylation-Based Telomere Length Estimator, the Mediterranean Diet and Genetics in a Spanish Population at High Cardiovascular Risk

Antioxidants, 2023-11, Vol.12 (11), p.2004

2023

Volltextzugriff (PDF)

Melanoma of unknown primary: New perspectives for an old story

Critical reviews in oncology/hematology, 2021-02, Vol.158, p.103208-103208, Article 103208

2021

Volltextzugriff (PDF)

Immunotherapies in ovarian cancer

European journal of cancer supplements, 2020-08, Vol.15, p.87-95

2020

Volltextzugriff (PDF)

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

Cell metabolism, 2017-10, Vol.26 (4), p.633-647.e7

2017

Volltextzugriff (PDF)

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Cancer chemotherapy and pharmacology, 2018-08, Vol.82 (2), p.285-298

2018

Volltextzugriff (PDF)

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study

British journal of cancer, 2021-10, Vol.125 (9), p.1261-1269

2021

Volltextzugriff (PDF)

Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?

Gynecologic oncology, 2022-02, Vol.164 (2), p.406-414

2022

Volltextzugriff (PDF)

1 – 25 von 143

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(134)
Mit Volltextzugriff
(121)

Publikationsform

Artikel
(142)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Paclitaxel alters melanogenesis and causes pigmentation in the skin of gynecological cancer patients

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

Timing of Meals and Sleep in the Mediterranean Population: The Effect of Taste, Genetics, Environmental Determinants, and Interactions on Obesity Phenotypes

Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus

Aurora kinases in ovarian cancer

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

Chronological Age Interacts with the Circadian Melatonin Receptor 1B Gene Variation, Determining Fasting Glucose Concentrations in Mediterranean Populations. Additional Analyses on Type-2 Diabetes Risk

Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways

Associations between the New DNA-Methylation-Based Telomere Length Estimator, the Mediterranean Diet and Genetics in a Spanish Population at High Cardiovascular Risk

Melanoma of unknown primary: New perspectives for an old story

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Immunotherapies in ovarian cancer

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers

Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?

Suchergebnisse filtern